Condition,"Comment/
Mutation Type",Comment
RPV=3,,This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated.
RPV=4,,This virus is predicted to have intermediate-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be contraindicated.
90I,Other,"V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
98G,NNRTI,A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.
100I,NNRTI,"L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it confers high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR and DOR."
100V,NNRTI,"L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it confers high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR and DOR. L100V is a rare mutations that likely has effects similar to L100I."
101E,NNRTI,"K101E is a non-polymorphic accessory mutation that confers intermediate resistance to NVP and RPV and low-level reductions in susceptibility to EFV, ETR, and DOR when it occurs with other NNRTI-resistance mutations."
101H,NNRTI,"K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, it contributes reduces susceptibility to these NNRTIs."
101NAT,Other,K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance.
101P,NNRTI,"K101P is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and ETR. Its does not appear to reduce DOR susceptibility."
101Q,Other,K101Q is a relatively non-polymorphic mutation that is weakly selected in persons receiving NVP and EFV. It is of uncertain phenotypic and clinical significance.
103EQ,NNRTI,K103E/Q are rare mutations that have not been associated with reduced NNRTI susceptibility.
103H,NNRTI,K103H is a rare non-polymorphic mutation that confers high-level resistance to NVP and EFV.
103N,NNRTI,K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM.
103R,Other,"K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
103S,NNRTI,"K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
103T,NNRTI,K103T is an extremely rare non-polymorphic mutation that appears to confer intermediate/high-level resistance to NVP but it has little if any effect on EFV susceptibility.
106A,NNRTI,"V106A is a non-polymorphic mutation that confers high-level resistance to NVP and DOR, and intermediate resistance to EFV. It is commonly selected in vitro and in vivo by DOR."
106I,NNRTI,V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility only in combination with other NNRTI-resistance mutations. It is commonly selected in persons receiving DOR in combination with mutations at position 227.
106M,NNRTI,V106M is a non-polymorphic mutation that confers high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it reduces DOR susceptibility about 3-fold.
106L,NNRTI,V106L is a non-polymorphic mutation occasionally selected by NNRTIs. It was reported in an isolate from one of the patients with VF on a DOR-containing regimen that had an approximately 15-fold reduced DOR susceptibility. Additional confirmatory phenotypic data are required.
108I,NNRTI,V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations.
132ML,Other,"I132M is an extremely rare non-polymorphic mutation associated with uncertain amount of reduced NVP and EFV susceptibility. I132L is a more common, non-polymorphic NNRTI-selected mutation that has not been well studied."
138A,NNRTI,E138A is a common polymorphic accessory mutation weakly selected in persons receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and RPV-containing regimens is likely to be minimal.
138K,NNRTI,"E138K is a non-polymorphic mutation selected in a high proportion of persons receiving RPV. It reduces RPV susceptibility 2 to 3-fold. In combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause VF on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR."
138QG,NNRTI,"E138Q/G are non-polymorphic accessory mutations selected by ETR occasionally NVP and EFV. They cause low-level reductions in susceptibility to NVP, RPV, and ETR."
138R,NNRTI,E138R is an extremely rare non-polymorphic accessory mutation selected in vitro by RPV. Its effect on NNRTI susceptibility has not been well studied.
179DE,NNRTI,"V179D/E are somewhat polymorphic accessory NNRTI-selected mutation. In combination with other NNRTI DRMs, they appear to contribute low-levels of reduced susceptibility to each of the NNRTIs. In particular, the combinations of K103R/V179D and V106I/V179D act synergistically to reduce NVP and EFV susceptibility."
179F,NNRTI,"V179F is a non-polymorphic mutation selected in combination with Y181C in persons receiving ETR. Alone it has little effect on NNRTI susceptibility, however in combination with Y181C it is associated with high-level reductions in ETR and RPV susceptibility."
179I,Other,"V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
179L,NNRTI,V179L is a rare non-polymorphic mutation listed as a RPV-associated resistance mutation by the FDA package insert. Its effects on NNRTI susceptibility have not been well studied.
179T,NNRTI,"V179T is a rare non-polymorphic mutation occasionally selected in persons receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility."
181C,NNRTI,"Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. Alone, it does not significantly reduce DOR susceptibility."
181FSG,NNRTI,Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V.
181IV,NNRTI,"Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV but not EFV. Their effects on DOR have not been well-characterized."
188C,NNRTI,"Y188C is a non-polymorphic mutation selected in persons receiving NVP and EFV. It confers high-level resistance to NVP and variable levels of reduced susceptibility to EFV. It appears to cause little if any reduction in susceptibility to RPV, ETR, or DOR."
188F,NNRTI,Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L.
188H,NNRTI,"Y188H is a non-polymorphic mutation selected in persons receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV. It appears to cause little if any reduction in susceptibility to RPV, ETR, or DOR."
188L,NNRTI,"Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
190A,NNRTI,"G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
190CTV,NNRTI,"G190C/T/V are rare non-polymorphic mutations that confer high-level resistance to NVP and EFV. Their effects on ETR, RPV, and DOR susceptibility are not known."
190EQ,NNRTI,"G190E is an uncommon non-polymorphic mutation associated with reduced replication capacity that confers intermediate to high-level resistance to each of the NNRTIs. G190Q is a rare NNRTI-selected mutation that confers high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
190S,NNRTI,G190S is a non-polymorphic mutation that confers high-level resistance to NVP and EFV. It may also be associated low-levels reductions in DOR susceptibility. It does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility.
221Y,NNRTI,"H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
225H,NNRTI,"P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
227C,NNRTI,"F227C is a nonpolymorphic mutation selected in persons receiving DOR and rarely in persons receiving ETR and RPV. It usually occurs in combination with other DRMs and in this setting has consistently been associated with the highest possible levels of DOR resistance. It is also usually associated with intermediate or high-level reductions in susceptibility to NVP, EFV, ETR, and RPV."
227ILV,NNRTI,F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR.
230I,NNRTI,M230I is a rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious.
230L,NNRTI,"M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
234I,NNRTI,"L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been well characterized."
236L,NNRTI,"P236L is a rare mutation selected commonly by DLV, which appears to have little if any effect on current NNRTIs."
238TN,NNRTI,"K238T/N are uncommon non-polymorphic mutations selected in persons receiving NVP and EFV usually in combination with K103N. Alone, K238T/N appear to have minimal effects on NNRTI susceptibility."
318F,NNRTI,"Y318F is a nonpolymorphic mutation that occurred in 2 of 10 persons with VF and HIVDR while receiving DOR. It confers about 11-fold reduced susceptibility to DOR but otherwise has minimal if any effect on NVP, EFV, and ETR."
348I,NNRTI,N348I is a non-polymorphic accessory mutation selected by NVP and EFV and the NRTIs AZT and D4T. Alone it reduces AZT and NVP susceptibility by about 3-fold and EFV susceptibility by 2-fold.